ライフサイエンスコーパス: gynecological

1 n plasma were determined in 61 patients with gynecological and breast cancers and 65 female patients

2 o achieve transgene expression in a range of gynecological and breast tumor lines.

3 a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BR

4 2 were surveyed about menstrual function and gynecological and obstetrical histories before and after

5 lysis, was observed in primary human breast, gynecological, and colon carcinomas, but not in stromal-

6 tastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas.

7 lon carcinoma cell lines as well as in human gynecological, breast, and central nervous system tumors

8 ide variety of human cancers, including most gynecological, breast, and colon cancers.

9 e about the impact of the different types of gynecological cancer and its treatment on sexual functio

10 Ovarian cancer (OC) is the most deadly gynecological cancer and unlike most other neoplasms, su

11 gher gelsolin (GSN) levels in chemoresistant gynecological cancer cells compared with their sensitive

12 2010, in which 27 surgeons from 20 tertiary gynecological cancer centers in Australia, New Zealand,

13 search Institute, Cancer Australia, National Gynecological Cancer Centre, and AstraZeneca.

14 varian cancer is the fourth leading cause of gynecological cancer death among women in the United Sta

15 metrial carcinomas represent the most common gynecological cancer in the United States, yet the molec

16 Endometrial cancer is the most common gynecological cancer in Western industrialized countries

17 riteria in Solid Tumors [RECIST] or modified Gynecological Cancer Intergroup CA-125), toxicity, progr

18 Ovarian cancer is a highly lethal gynecological cancer, and its causes remain to be unders

19 s ovarian carcinoma (HGSOC), the most lethal gynecological cancer, often leads to chemoresistant dise

20 of the standard care of women diagnosed with gynecological cancer.

21 Ovarian cancer is the most lethal gynecological cancer.

22 may be independently associated with risk of gynecological cancers beyond the contribution of the ind

23 orrect use of tumor markers in patients with gynecological cancers can make an impact on management o

24 for as many deaths as breast cancer and all gynecological cancers combined.

25 ncer accounts for more deaths than all other gynecological cancers combined.

26 reduced BRCA1 expression might predispose to gynecological cancers indirectly, by influencing ovarian

27 ues report the identification of a subset of gynecological cancers with repressed expression of the p

28 antly associated with the risk of breast and gynecological cancers, and it may be utilized as a valua

29 Ovarian cancer is the most lethal of all gynecological cancers, and there is an urgent unmet need

30 HGSC) results in the highest mortality among gynecological cancers, developing rapidly and aggressive

31 ge about the nature of sexual dysfunction in gynecological cancers, highlighting recent publications

32 arian cancer (EOC) is one of the most common gynecological cancers, with diagnosis often at a late st

33 varian cancer is a leading cause of death in gynecological cancers.

34 alignancy and has the worst prognosis of all gynecological cancers.

35 orm, DeltaNp73, is upregulated in breast and gynecological cancers.

36 , with the highest mortality rate of all the gynecological cancers.

37 Ovarian cancer is the most deadly of all gynecological cancers.

38 remains the most common cause of death from gynecological cancers.

39 lity of screening and access to high-quality gynecological care.

40 ed 18-35 years who self-referred for routine gynecological care.

41 liver disease and details of pregnancies and gynecological care.

42 nt for an underlying bleeding disorder after gynecological causes are ruled out.

43 plays an important role in the regulation of gynecological cell fate as reflected in dysregulation in

44 ecific regulatory signatures compared to non-gynecological cell types.

45 d cervical HPV infection was nested within a gynecological cohort of HIV-infected women.

46 ctional anal screening study was nested in a gynecological cohort of HIV-infected women.

47 ); reproductive health factors, particularly gynecological complaints such as vaginal discharge (OR,

48 Endometriosis is a common gynecological condition with complex etiology defined by

49 tritional biomarkers associated with several gynecological conditions among US women with or at risk

50 This relation among HIV, nutrition, and gynecological conditions is complex and has rarely been

51 l stages of ovarian cancer and common benign gynecological conditions were represented.

52 icronutrient serum concentrations to various gynecological conditions, producing partially adjusted o

53 at include compromised nutrition and adverse gynecological conditions.

54 trient concentrations with the prevalence of gynecological conditions.

55 Patients seen later in gynecological consultation had more severe lesions than

56 ptoms are one of the most common reasons for gynecological consultation.

57 lowed after transplantation in a specialized gynecological consultation.

58 nd examination performed at admission to the Gynecological Department excluded adnexal neoplasm.

59 ic surgery did not benefit women with benign gynecological disease in terms of effectiveness or safet

60 ntial value of ER antagonists in controlling gynecological disease in the lower reproductive tracts i

61 endent, progesterone-resistant, inflammatory gynecological disease of reproductive age women.

62 Endometriosis is a common gynecological disease that affects approximately 10% of

63 Ovarian cancer is a lethal gynecological disease that is characterized by peritonea

64 y subjects or in control subjects with other gynecological disease.

65 ut not proven, in the pathogenesis of common gynecological diseases such as endometriosis and rarer e

66 is one of the most common manifestations of gynecological diseases, and is a prime indication for hy

67 Racial disparities exist in gynecological diseases.

68 vorably indicated in endometriosis and other gynecological diseases.

69 Endometriosis is a gynecological disorder affecting 6%-10% of all women in

70 Endometriosis is an incurable gynecological disorder characterized by debilitating pai

71 dometriosis is a heritable hormone-dependent gynecological disorder, associated with severe pelvic pa

72 ontraception, and incidence of pregnancy and gynecological disorders.

73 g has important implications for more common gynecological entities with debatable pathogenesis, such

74 n, because up to half of women with a normal gynecological evaluation will have laboratory abnormalit

75 ified in women with menorrhagia and a normal gynecological evaluation, as 11-16% of them will meet th

76 Participants underwent a gynecological examination at baseline and at approximate

77 ional attainment, pregnancy-related factors, gynecological factors, urological and gastrointestinal t

78 Bacterial vaginosis (BV) is the most common gynecological infection in the United States.

79 9 could induce susceptibility to urinary and gynecological infection.

80 Gynecological investigation was unrevealing.

81 identified cases with poor prognosis in both gynecological LMS (P = 0.00006) and nongynecological LMS

82 In gynecological LMS, a similar trend was noted but did not

83 In gynecological LMS, the coordinate expression of these fo

84 Gastrointestinal and gynecological malignancies disseminate in the peritoneal

85 ncer is the leading cause of death among all gynecological malignancies due to the development of acq

86 the leading cause of death among women from gynecological malignancies inthe United States.

87 cer is one of the leading causes of death in gynecological malignancies, and the resistance to chemot

88 er, which is the leading cause of death from gynecological malignancies, is a heterogeneous disease k

89 n high levels in the plasma of subjects with gynecological malignancies.

90 ancer is the leading cause of fatality among gynecological malignancies.

91 the leading cause of death among women with gynecological malignancies.

92 ed Sates and the leading cause of death from gynecological malignancies.

93 n cancer is the leading cause of death among gynecological malignancies.

94 herapeutic intervention in major subtypes of gynecological malignancies; however, the receptor levels

95 an cancer is the leading cause of death from gynecological malignancy and has the worst prognosis of

96 an cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of

97 cer (EOC) is the leading cause of death from gynecological malignancy in the developed world, account

98 Endometrial cancer is the most common gynecological malignancy in the developed world.

99 Ovarian cancer is currently the most lethal gynecological malignancy in the United States.

100 Endometrial carcinoma is the most common gynecological malignancy in the United States.

101 Serous ovarian carcinoma is the most lethal gynecological malignancy in Western countries.

102 Ovarian cancer is a gynecological malignancy that is commonly treated by cyt

103 treatment of ovarian cancer, the most lethal gynecological malignancy worldwide, is not known.

104 Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate o

105 ancer (EOC), the leading cause of death from gynecological malignancy, is a poorly understood disease

106 enesis of ovarian carcinoma, the most lethal gynecological malignancy, is unknown because of the lack

107 Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases projecte

108 Endometrial cancer is the most common gynecological malignancy, with more than 280,000 cases o

109 l biomarker associated with life-threatening gynecological malignancy.

110 Ovarian cancer remains the most lethal gynecological malignant tumor.

111 polymerase chain reaction (PCR) results, and gynecological manifestations of FGS in women with differ

112 ter sexual risk-taking, report prevalence of gynecological morbidity (GM), and test whether moderniza

113 Uterine leiomyomata are a major source of gynecological morbidity and are 2-3 times more prevalent

114 were abdominal (n = 113), ENT (n = 71), and gynecological (n = 58) procedures.

115 at clinically can be confused with malignant gynecological neoplasms demonstrated DNA integrity index

116 represents 12 surgical specialties: general, gynecological, neurosurgical, oral, orthopedics, otolary

117 and temporal links between neurological and gynecological operations in 857 sCJD cases referred from

118 is characteristically detected in women with gynecological or breast adenocarcinoma.

119 rent or past axis I psychiatric diagnosis or gynecological or other medical illness.

120 a long distance signaling between tissues of gynecological origin.

121 V-uninfected women with both nutritional and gynecological outcomes were analyzed from a cross-sectio

122 osis 'pelvic pain', traditionally limited to gynecological pains, has now been generalized to include

123 p reported greater mean symptom severity for gynecological problems (0.29 vs 0.19, P<.001), vasomotor

124 , those in the tamoxifen group reported more gynecological problems, vasomotor symptoms, leg cramps,

125 Tubal sterilization is a common gynecological procedure that may be associated with othe

126 occurs more frequently during obstetric and gynecological procedures than during most other surgical

127 um that can cause toxic shock syndrome after gynecological procedures.

128 Detection and excision of tumors by a gynecological surgeon improved with SWNT image guidance

129 ho were recruited to the study by consultant gynecological surgeons from 18 UK hospitals between Febr

130 rs) between cases undergoing neurosurgery or gynecological surgery INTERPRETATION: It is unlikely tha

131 time of either elective cesarean section or gynecological surgery.

132 Gynecological symptoms may be somatic equivalents of CMD

133 ated breast cancer, although side effects in gynecological tissues are unacceptable.

134 l surfaces of the human gastrointestinal and gynecological tracts and causes disease in a wide range

135 tly colonizes the human gastrointestinal and gynecological tracts and less frequently causes deep tis

136 As NSAIDs are already in routine use in gynecological treatment regimens and have acceptable saf

137 and their receptors in the carcinogenesis of gynecological tumors.

138 ith the highest mortality rate among all the gynecological tumors.

139 for detection of folate receptor-expressing gynecological tumors.

140 g (nonsmall cell), breast, digestive system, gynecological, urinary system, or head and neck were inc

141 were recruited to the study during a routine gynecological visit.